摘要:
The invention relates to a method by which expression cDNA clone banks are screened by means of IgE antibodies derived from the sera of allergic individuals, or by means of monoclonal or polyconal antibodies. This type of screening is used for the detection of polynucleotides whose open-reading frames code for allergenically active proteins. These proteins are characterized in that their biological activity as allergens is equal to that of plant allergens occurring in nature.
摘要:
The invention relates to a method by which expression cDNA clone banks are screened by means of IgE antibodies derived from the sera of allergic individuals, or by means of monoclonal or polyclonal antibodies. This type of screening is used for the detection of polynucleotides whose open-reading frames code for allergenically active proteins. These proteins are characterized in that their biological activity as allergens is equal to that of plant allergens occurring in nature.
摘要:
This invention provides recombinant DNA molecules which code for polypeptides that exhibit the antigenicity of an Aln g I allergen of alder, Alnus sp., of a Cor a I allergen of hazel or of a Bet v I allergen of birch and other plants of the order Fageles, and for polypeptides comprising at least one epitope thereof, as well as nucleic acids which under stringent conditions hybridize with such DNA sequences or are derivable from such sequences by degeneracy of the genetic code. In addition, methods are described for using the polypeptides coded by these DNA molecules and their use in the diagnosis or therapy of allergic diseases.
摘要翻译:PCT No.PCT / EP91 / 01479 371日期:1992年6月1日 102(e)日期1992年6月1日PCT 1991年8月6日PCT PCT。 出版物WO92 / 02621 日本1992年2月20日本发明提供重组DNA分子,其编码多肽,其表现出榛子al an an a a a a haz haz haz haz of of of of and and and and and and and and and and and and and and and and and and and and and 对于包含其至少一个表位的多肽,以及在严格条件下与这些DNA序列杂交或通过遗传密码的简并性可从这些序列衍生的核酸,其它植物的Fageles序列。 此外,描述了使用由这些DNA分子编码的多肽及其在过敏性疾病的诊断或治疗中的用途的方法。
摘要:
The invention provides recombinant DNA molecules which code for proteins or polypeptides that exhibit the antigenicity of a P14 allergen of birch Betula verrucosa and other plants of the order Fagales, and for polypeptides comprising at least one epitope thereof, as well as nucleic acids which under stringent conditions hybridize with such DNA sequences or are derivable from such sequences by degeneracy of the genetic code. A method is provided that permits purification of P14 allergens or cross-reactive allergens by means of binding to poly(L-proline). In addition, methods are described for making the proteins and polypeptides coded by these DNA molecules and their use in the diagnosis or therapy of allergic diseases.
摘要:
The invention provides recombinant DNA molecules which code for polypeptides that exhibit the antigenicity of a P14 allergen of birch Betula verrucosa and other plants of the order Fagales, and for polypeptides comprising at least one epitope thereof, as well as nucleic acids which under stringent conditions hybridize with such DNA sequences or are derivable from such sequences by degeneracy of the genetic code. A method is provided that permits purification of P14 allergens or cross reactive allergens by means of binding to poly(L-proline). In addition, methods are described for making the proteins and polypeptides coded by these DNA molecules and their use in the diagnosis or therapy of diseases.
摘要:
Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.
摘要:
The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.
摘要:
The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are identical to at least three amino acids which appear in close vicinity on the molecular surface of an allergenic protein, and said at least three amino acids are solvent-exposed amino acids in the allergenic protein. The invention also concerns a method for the preparation of the pharmaceutical composition.
摘要:
The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.
摘要:
The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.